Replies to post #84028 on Biotech Values

[DewDiligence]

Well, that proves three things:

1. Someone working for PBCI was an idiot;
2. The SEC does not read most filings; and
3. Never say never*.

Nice detective work, although it doesn’t change the validity of the point in #msg-41814934. What investors like wallstarb sloppily call a secondary offering is properly called a follow-on offering (to distinguish it from an IPO).

*My favorite example of this is in #msg-10536647 :- )